PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29339442-3	2018	METHODS: We prepared and tested a library of analogs of palmitoyl 4-methylumbelifferyl esters to find a highly active and specific substrate for LAL in DBS.	dbs	152-155	lipase A, lysosomal acid type	Homo sapiens	145-148	
29339442-6	2018	RESULTS: The ester formed between palmitic acid and 4-propyl-8-methyl-7-hydroxycoumarin (P-PMHC) was found to be >98% selective for LAL in DBS based on the sensitivity of its activity to the LAL-specific inactivator Lalistat-2 and the fact that the activity was close to zero using DBS from patients previously shown to be LAL-deficient.	dbs	142-145	lipase A, lysosomal acid type	Homo sapiens	135-138	
29339442-6	2018	RESULTS: The ester formed between palmitic acid and 4-propyl-8-methyl-7-hydroxycoumarin (P-PMHC) was found to be >98% selective for LAL in DBS based on the sensitivity of its activity to the LAL-specific inactivator Lalistat-2 and the fact that the activity was close to zero using DBS from patients previously shown to be LAL-deficient.	dbs	285-288	lipase A, lysosomal acid type	Homo sapiens	135-138	
29339442-9	2018	CONCLUSIONS: The new assay can measure LAL in DBS with a single measurement compared with the previous method involving 2 assays done in parallel.	dbs	46-49	lipase A, lysosomal acid type	Homo sapiens	39-42	
31505261-3	2019	METHODS: LAL activity was measured (i) on dried blood spots (DBS) from NAFLD patients and dyslipidemic subjects without fatty liver and (ii) on liver biopsies from NAFLD patients.	dbs	61-64	lipase A, lysosomal acid type	Homo sapiens	9-12	
31505261-6	2019	LAL activity measured in liver biopsies from NAFLD patients was highly correlated to that measured on DBS and was independent of LAL expression in the liver.	dbs	102-105	lipase A, lysosomal acid type	Homo sapiens	0-3	
31505261-7	2019	In a fully adjusted model, LAL activity on DBS was associated only with platelets and, when normalized by platelet count, it did not differ according to fibrosis stage.	dbs	43-46	lipase A, lysosomal acid type	Homo sapiens	27-30	
24295952-3	2014	Recently, Hamilton used a fluorometric enzyme assay with 4-MU derivatives to measure the LAL activity in DBS.	dbs	105-108	lipase A, lysosomal acid type	Homo sapiens	89-92	
28532785-6	2017	With the increase in DBS LAL testing since the original publication of this method, a need to optimise assay performance has been identified.	dbs	21-24	lipase A, lysosomal acid type	Homo sapiens	25-28	
28238812-1	2017	BACKGROUND: We aimed to evaluate the influence of white blood cell (WBC) and platelet (PLT) counts on dried blood spot (DBS)-determined lysosomal acid lipase (LAL) activity in a large group of healthy subjects.	dbs	120-123	lipase A, lysosomal acid type	Homo sapiens	136-157	
28238812-1	2017	BACKGROUND: We aimed to evaluate the influence of white blood cell (WBC) and platelet (PLT) counts on dried blood spot (DBS)-determined lysosomal acid lipase (LAL) activity in a large group of healthy subjects.	dbs	120-123	lipase A, lysosomal acid type	Homo sapiens	159-162	
28238812-3	2017	Complete clinical biochemistry and LAL activity in DBS were determined.	dbs	51-54	lipase A, lysosomal acid type	Homo sapiens	35-38	
28238812-5	2017	Univariate and multivariate analyses to DBS-LAL activity were performed.	dbs	40-43	lipase A, lysosomal acid type	Homo sapiens	44-47	
28238812-8	2017	However, LAL activity in DBS correlated more strongly with that in PLTs (r=0.65, p<0.001) than with that in WBCs (r=0.49, p<0.01).	dbs	25-28	lipase A, lysosomal acid type	Homo sapiens	9-12	
28238812-9	2017	Consistently, in the multivariate model, DBS-LAL activity was independently associated only with PLT count (beta=0.39, p<0.001).	dbs	41-44	lipase A, lysosomal acid type	Homo sapiens	45-48	
28238812-10	2017	CONCLUSIONS: PLT number may impact on the result of the DBS-LAL test, and a consideration of PLT count is recommended before interpreting LAL activity in DBS.	dbs	56-59	lipase A, lysosomal acid type	Homo sapiens	60-63	
28238812-10	2017	CONCLUSIONS: PLT number may impact on the result of the DBS-LAL test, and a consideration of PLT count is recommended before interpreting LAL activity in DBS.	dbs	154-157	lipase A, lysosomal acid type	Homo sapiens	138-141	
28587063-5	2017	For each patient, LAL activity was determined on peripheral dried blood spots (DBS) and correlated with clinical and laboratory data.	dbs	79-82	lipase A, lysosomal acid type	Homo sapiens	18-21	
28587063-9	2017	LAL activity is also correlated with platelet and white blood cell count, suggesting an analytic interference of portal-hypertension-induced pancytopenia on DBS-determined LAL activity.	dbs	157-160	lipase A, lysosomal acid type	Homo sapiens	0-3	
28587063-9	2017	LAL activity is also correlated with platelet and white blood cell count, suggesting an analytic interference of portal-hypertension-induced pancytopenia on DBS-determined LAL activity.	dbs	157-160	lipase A, lysosomal acid type	Homo sapiens	172-175	
24295952-7	2014	The LAL activity in DBS was measured in 51 normal controls, seven obligate carriers and seven patients with CESD.	dbs	20-23	lipase A, lysosomal acid type	Homo sapiens	4-7	
24295952-8	2014	The average LAL activities +- SD in the DBS from the normal, obligate carriers and CESD patients were 0.68 +- 0.2 (range: 0.3-1.08), 0.21 +- 0.1 (range: 0.11-0.41) and 0.02 +- 0.02 (range: 0-0.06) nmol/punch/h, respectively.	dbs	40-43	lipase A, lysosomal acid type	Homo sapiens	12-15